This week, we round out our AML series with a detailed discussion about the approach to management of relapsed and refractory disease. This has been a VERY long road going through all management of AML. We hope that you have continued to build on our discussions week-to-week. An exciting treatment paradigm that is ever-evolving!

Episode contents:

- How do we define primary induction failure in AML?

- What are options for treatment of refractory disease? What is the mechanism of action of these treatment options?

- What are options for relapsed disease?

- What targeted therapies are available for relapsed AML?

****This episode is sponsored by our global research partners! Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email

** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes

Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!

Twitter: @TheFellowOnCall

Instagram: @TheFellowOnCall

Listen in on: Apple Podcast, Spotify, and Google Podcast

Episode 126: AML Series, Pt 12 - Treatment of patients with relapsed/refractory disease

The Fellow on Call: The Heme/Onc Podcast

Episode 126: AML Series, Pt 12 - Treatment of patients with relapsed/refractory disease